)n March 10, 2023 at 13:45:09 ET an unusually large $52.50K block of Put contracts in Cardiff Oncology (CRDF) was bought, with a strike price of $2.50 / share, expiring in 161 days (on August 18, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 1.00 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in CRDF options.

This trade was first picked up on Fintel’s real time Unusual Option Trades tool, where unusual option trades are highlighted.

Analyst Price Forecast Suggests 353.33% Upside

As of March 10, 2023, the average one-year price target for Cardiff Oncology is $8.16. The forecasts range from a low of $5.05 to a high of $14.70. The average price target represents an increase of 353.33% from its latest reported closing price of $1.80.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Cardiff Oncology is $0MM, a decrease of 49.00%. The projected annual non-GAAP EPS is -$1.09.

What is the Fund Sentiment?

There are 91 funds or institutions reporting positions in Cardiff Oncology. This is a decrease of 12 owner(s) or 11.65% in the last quarter. Average portfolio weight of all funds dedicated to CRDF is 0.01%, a decrease of 19.28%. Total shares owned by institutions decreased in the last three months by 2.98% to 7,919K shares. The put/call ratio of CRDF is 0.13, indicating a bullish outlook.

What are Large Shareholders Doing?

VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 1,286K shares representing 2.88% ownership of the company. No change in the last quarter.

Artal Group holds 750K shares representing 1.68% ownership of the company. No change in the last quarter.

Laurion Capital Management holds 722K shares representing 1.62% ownership of the company. No change in the last quarter.

VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 591K shares representing 1.32% ownership of the company. In it’s prior filing, the firm reported owning 590K shares, representing an increase of 0.15%. The firm decreased its portfolio allocation in CRDF by 12.26% over the last quarter.

Renaissance Technologies holds 491K shares representing 1.10% ownership of the company. In it’s prior filing, the firm reported owning 422K shares, representing an increase of 14.05%. The firm increased its portfolio allocation in CRDF by 2.22% over the last quarter.

Cardiff Oncology Background Information
(This description is provided by the company.)

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to overcome resistance, improve response to treatment and increase overall survival. The company is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Cardiff has three clinical programs that have demonstrated the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021.

This article originally appeared on Fintel